Posts Tagged: "Michael J. Fox Foundation"

Successful Phase 1 Trial for Parkinson’s Vaccine

The study looked at groups of patients receiving various levels of the PD01A vaccine and evaluated them over a 12-month period. Patients receiving the vaccine were given PD01A subcutaneously in four vaccinations, either in doses of 15 micrograms or 75 micrograms… Of those who were immunized, 15 patients out of every 24 saw an increase in alpha-synuclein-specific antibodies. Interestingly, the antibody response was greater in the group of patients receiving the lower 15 microgram dose as compared to the group receiving the 75 micrograms of PD01A per vaccination. Also important was the fact that the vaccination was tolerated at the dosage levels administered and that there were no signs of a negative autoimmune response…